财中社11月27日电科伦博泰生物-B(06990)发布公告,宣布公司首款用于治疗不可切除的局部晚期或转移性三阴性乳腺癌(TNBC)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT)已获得国家药品监督管理局(NMPA)批准上市。该批准基于一项针对至少接受过两种系统治疗的TNBC患者的随机、对照3期研究OptiTROP-Breast01的积极结果,显示出与化疗相比,sac-TMT在无进展生存期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.